News und Analysen
Valbiotis kündigt bevorstehende organisatorische Änderungen im Vorstand an
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentations at two upcoming investor conferences
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2021. Unless otherwise stated, all comparisons
Valbiotis Announces Upcoming Organizational Changes of its Board of Directors
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
DGAP-HV: Bayer Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 29.04.2022 in Virtuell/Leverkusen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302006217/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Simulations Plus to Present at Raymond James Institutional Investors Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women
Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06482077 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug
DGAP-News: Evotec präsentiert strategischen Fahrplan für Präzisionsmedizin und bestätigt Ziele des Aktionsplans 2025 auf dem Capital Markets Day
DGAP-News: Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day
NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and year
FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the FDA has granted Breakthrough Device Designation for
AEVIS VICTORIA SA (AEVS:SW): Division Hospitality erwirbt Hotel L'Oscar im Zentrum von London für GBP 60 Millionen.
AEVIS VICTORIA SA (AEVS:SW): Hotel division acquires hotel L'Oscar in central London for GBP 60 million.
Premier, Inc. to Participate in Upcoming Investor Conferences
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in the following investor
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial), a pivotal Phase 3 study evaluating its Clostridioides difficile (C. difficile)
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar
Vifor Pharma Schweiz AG gab heute die Markteinführung des Calcifediol-Retardpräparats Rayaldee® in der Schweiz bekannt. Rayaldee® ist die erste und einzige in Europa zugelassene orale Therapie
DGAP-News: Evotec erweitert molekulare Patientendatenbank mit einzigartiger Nephrologie-Kohorte der Universität Bristol
DGAP-News: Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
-
Cowen 42nd Annual Health Care
Acadia Healthcare Reports Fourth Quarter 2021 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2021.
Fourth Quarter Highlights
-
Revenue totaled $593.5